The prognostic value of interim positron emission tomography scans combined with immunohistochemical data in diffuse large B-cell lymphoma.
The treatment of hematologic malignancies is moving towards risk-stratified directed therapy, whereby treatment is based on the disease's biological characteristics and response to treatment. We investigated whether BCL2 and BCL6 status could add to the prognostic information yielded by an interim positron emission tomography (PET) scan in the ability to predict outcome. Negative interim scans and BCL2-negative status correlated with continuing remission (p<0.005) at a median follow up of 24 months.
Fields
Paul A
PA
Mikhaeel
George
G
Hutchings
Martin
M
van der Walt
Jon
J
Nunan
Tom
T
Schey
Steve A
SA
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis*; D001706:Biopsy; D004268:DNA-Binding Proteins / Q000032:analysis*; D018450:Disease Progression; D005500:Follow-Up Studies; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000737:chemistry / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000401:mortality / Q000473:pathology; D049268:Positron-Emission Tomography; D011379:Prognosis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000032:analysis*; D051560:Proto-Oncogene Proteins c-bcl-6; D012074:Remission Induction; D012189:Retrospective Studies; D016896:Treatment Outcome
C084103:BCL6 protein, human; D014408:Biomarkers, Tumor; D004268:DNA-Binding Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D051560:Proto-Oncogene Proteins c-bcl-6